[Four different treatment protocols for Helicobacter pylori infection--a clinical pilot study]

A pilot clinical trial specially designed to test four different treatment regimens of Helicobacter pylori infection was performed among hospitalized and outpatient based patients in Clinical Centre University of Sarajevo, Gastroenterohepatology Clinics. Another objective was to assess Helicobacter pylori total cradication rates, partial cradication rates and after treatment persistent Helicobacter pylori infection rates among patients with clinically proven peptic ulcer disease (PUS). All patients randomly assigned into four groups had endoscopically and Helicourcasa test (HUT Astra) proven peptic ulcers. Each group was treated with one of the following four triple regimens: ranitidine + amoxicillin + metronidazole (RAM); ranitidine + clarithromycin + metronidazole (RCM); omeprazole + amoxicillin + metronidazole (OAM) and omeprazole + clarithromycin + m etronidazole (OCM). All triple regimens were given twice-a-day for one week following either ranitidine or omeprazole for two weeks depending of basic regimens. The highest Helicobacter pylori eradication was produced with OCM regimens (91.7%). Using same regimens we found the lowest partial eradication rate of all regimens (8.3%) and no persistency of H. pylori after the treatment. The lowest total eradication rate was found using RCM regimens (67.7%), while there was no difference in the cure rate between OAM (76.9%) and RAM (77.3%) regimens. If it is applicable, recommended treatment regimen as a first choice for proven H. pylori infection is OCM.